Newark, NJNCT06140134Now EnrollingIRB Ready

Intrahepatic Cholangiocarcinoma Clinical Trial in Newark, NJ

Access cutting-edge intrahepatic cholangiocarcinoma treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.

Sponsored by Rutgers, The State University of New Jersey

Quick Self-Assessment

See if you qualify for this Newark location

Preparing your pre-screening questions…

Expert Care in Newark

Access intrahepatic cholangiocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related intrahepatic cholangiocarcinoma treatment provided free

Apply for This Newark Location

Check if you qualify for this intrahepatic cholangiocarcinoma clinical trial in Newark, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newark

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newark site if eligible
  4. 4Begin participation

About This Intrahepatic Cholangiocarcinoma Study in Newark

The aim of the current study is to determine the potential efficacy of liver transplantation in the form of patients' overall survival (OS) after neoadjuvant systemic therapy in patients with biologically responsive locally advanced non-metastatic intrahepatic cholangiocarcinoma (iCCA) in comparison to patients historically treated with chemotherapy alone.

Sponsor: Rutgers, The State University of New Jersey

Who Can Participate

Inclusion Criteria

Age ≥18 years of age on the day of consenting to the study.
Patients must have histologically confirmed diagnosis of locally advanced intrahepatic cholangiocarcinoma
Confirmed diagnosis of locally advanced unresectable iCCA with no vascular invasion, lymph node, or extrahepatic disease.
Unresectable disease based on tumor location or underlying liver disease
Patients must have ≥ 6 months of disease stability or tumor regression on neoadjuvant therapy. In cases in which patients had received second-line therapy, disease must also have been controlled for ≥ 6 months on that regimen.
Patients who had previous surgical resection for iCCA are eligible if surgery occurred more than 6 months prior to listing, and patients have had ≥ 6 months of disease stability or response on therapy.
ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A).
Patients must have organ and marrow function acceptable for liver transplantation per institutional protocol:
If history of chronic hepatitis B virus (HBV) infection, viral load should be undetectable on suppressive therapy.
If history of chronic hepatitis C virus (HCV) infection, patients should have undetectable HCV viral load.
Women of child-bearing years must have contraception plan in place from the time of study enrollment until at least one year following liver transplant.
Ability to understand and the willingness to sign a written informed consent document
Meets all other medical and psychosocial criteria for liver transplant
Demonstrate ability to comply with study procedures

Exclusion Criteria

Age \<18 years of age on the day of consenting to the study.
Patients who have extrahepatic metastases, lymph node involvement, invasion or encasement of major hepatic vascular structures, perforation of the visceral peritoneum, invasion of extrahepatic structures, invasion of perihilar fat, periductular invasion, concurrent hepatoma or mixed hepatocellular cholangiocarcinoma.
Concurrent severe and/or uncontrolled concurrent illness including, but not limited to, ongoing or active infection, acute fulminant liver failure, symptomatic congestive heart failure, unstable angina pectoris, severe uncorrected coronary artery disease, severe cerebrovascular disease, severe pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements and that would exclude the patient from eligibility for liver transplantation per institutional protocol.
Prior solid organ or bone marrow transplant
Dependent on ≥2 IV inotropic support to maintain hemodynamics
Previous (within the past 5 years) or concurrent presence of other cancer, except non-melanoma skin cancer and in situ carcinomas.
Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score \>1 (Karnofsky \<70%, see Appendix A).
Unable to understand and sign a written informed consent document
Untreated viral hepatitis
Pregnant or breast-feeding women
HIV-infected patients

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newark?

Yes, this clinical trial (NCT06140134) has an active research site in Newark, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Intrahepatic Cholangiocarcinoma Treatment Options in Newark, NJ

If you're searching for intrahepatic cholangiocarcinoma treatment options in Newark, NJ, this clinical trial (NCT06140134) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced intrahepatic cholangiocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all intrahepatic cholangiocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Newark, NJ

See all liver cancer clinical trials recruiting in Newark — not just this study.

Browse Liver Cancer Trials in Newark →

Browse More Trials by Condition

Liver Cancer TrialsGallbladder Cancer TrialsRheumatoid Arthritis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Newark?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newark, NJ